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tuberculin skin testMethods: For this prospective, cross-sectional study, HIV-infected and -uninfected patients
from a regional hospital and medical center in Taiwan were enrolled. Results of the two IGRAs
[QuantiFERON-TB Gold (QFT-G) and QuantiFERON-TB Gold In-Tube (QFT-GIT)] and the TSTwere
compared. Risk factors for positivity were analyzed.
Results: We recruited 233 patients [198 (85%) men; mean age, 39.4 years]. Most patients (74%)
were BCG vaccinated. The prevalence of LTBI was estimated to be 22.8% by TST, 15.9% by QFT-
G, and 20.6% by QFT-GIT. HIV-infected individuals had fewer positive QFT-GIT [7.0% vs. 28.6%,
p < 0.001, adjusted odds ratio (aOR)Z 0.28, p Z 0.05] and TST results, and more indetermi-
nate QFT-G responses (9.3% vs. 0.7%, p Z 0.002). Concordance between IGRAs and TST was
very poor in HIV-infected patients (k < 0.05). Independent risk factors for IGRA positivity were
increasing age (QFT-G: aOR Z 1.98, p Z 0.03; QFT-GIT: aOR Z 2.00, p Z 0.01) and IDUs
(aOR Z 4.33, p Z 0.05 by QFT-G).
Conclusion: HIV-infected persons had a significantly lower response to both IGRAs and TST.
High discordance was found between the two generations of IGRAs and between IGRAs and
TST. Increasing age, a known risk factor for LTBI, was significantly associated with IGRAs,
but not with TST.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The World Health Organization (WHO) estimated that 1.1
million (13%) of the 8.6 million people worldwide who
developed tuberculosis (TB) in 2012 are those living with
human immunodeficiency virus (HIV).1 TB remains the
leading cause of death in HIV-infected persons, and at least
one in four deaths among people living with HIV can be
attributed to TB.2 The TB case-fatality rate is markedly
increased among patients with HIV in the context of high TB
incidence and HIV prevalence.3 In 2012, 0.3 million (23%) of
the 1.3 million deaths due to TB are considered to be
related to HIV.
People latently infected with Mycobacterium tubercu-
losis are the major reservoir of potential, active TB disease,
especially among high-risk groups.4 Both HIV patients and
intravenous drug users (IDUs) are considered high-risk groups
for active TB disease. HIV-infected patients are at the
greatest risk of progression from latent TB infection (LTBI) to
active disease,5 with a lifetime risk of progression of 30%,
compared with 10% in the general population.6 IDUs are also
associated with a higher prevalence of LTBI and incidence of
TB.7 Among HIV-negative IDUs, the incidence of TB remains
six times higher than in the general population.8
Therefore, identification and treatment of LTBI in high-
risk groups is an important strategy that can lower the risk of
developing active TB disease and effectively reduce the
number of future potential sources of infection.9,10 WHO
recommends 12 collaborative HIV/TB activities, including
the “Three I’s for HIV/TB” [isoniazid preventive treatment
(IPT), intensified case finding, and infection control for TB],
as core prevention, care, and treatment services for HIV
infection.1 Antiretroviral therapy (ART) is a critical inter-
vention for reducing the risk of TB morbidity and mortality
among people living with HIV. Although ART reduces the risk
of TB disease by 65%,11 the incidence of HIV-related TB re-
mains unacceptably high.12,13 IPT significantly reduces TB
diseases in HIV-infected patients who have a positive tuber-
culin skin test (TST),14 and the combination of IPT with ART
achieves an 85% reduction in the incidence of TB.15The diagnosis of LTBI traditionally depended on TST,
which involves measurement of the transverse diameter of
induration after an intradermal injection of tuberculin. It is
easy to perform and cheap, but has the drawbacks of cross-
reacting to nontuberculous mycobacterium (NTM) and Ba-
cillus Calmette-Gue´rin (BCG) vaccination, anergy in immu-
nocompromised hosts, the need of return visit for the test
result interpretation, and the boosting phenomenon.16
Interferon-gamma (IFN-g) release assays (IGRAs) are
recently developed in vitro assays that are based on IFN-g
production in response to M. tuberculosis-specific antigens,
early secreted antigenic target 6-kDa protein (ESAT-6), and
culture filtrate protein-10 (CFP-10). IGRAs have several ad-
vantages over TST, including a higher specificity without
cross-reactivity with BCG strains and most NTM.14
QuantiFERON-TB Gold (QFT-G; Cellestis Ltd, Victoria,
Australia) is a whole-blood assay that uses enzyme-linked
immunosorbent assay for detection of IFN-g responses. The
novel in-tube version of QFT-G contains a third of M. tuber-
culosis antigen [TB 7.7; QuantiFERON-TB Gold In-Tube (QFT-
GIT)].10 QFT-GIT had been approved for use in Europe in 2005
and received approval from the United States Food and Drug
Administration in 2007 and is recommended as the diagnostic
tool for LTBI by Centers for Disease Control and Prevention.1
Taiwan is a country with a low HIV prevalence and an
intermediate TB burden. Since 1965, the universal immu-
nization program included neonatal BCG vaccination, and
the national coverage reached 99.8% in 2004.17 By 2012, the
total number of HIV patients in Taiwan was 24,239 (9725 of
whom had developed full-blown acquired immunodefi-
ciency syndrome with 3771 deaths). The annual incidence
of TB infection was 53.0/100,000 individuals in 2012.18 Of
all new TB cases in 2010, 0.8% had HIV co-infection, and
among those aged 15e49 years, 2.5% were HIV positive.19
The HIV prevalence in IDUs was estimated to be between
12.3% and 25.5%, compared with 0.08% in the general
population.20
The sensitivity of IGRAs and TST is diminished in HIV-
infected patients because of anergy associated with a low
cluster of differentiation 4 (CD4) cell count.21 There are
Latent TB infection by IGRA and TST in HIV and IDUs 731limited data describing the difference between the two
generations of QFTs in the HIV-infected population.
The purpose of our study is to determine the prevalence
of LTBI in HIV-infected and HIV-uninfected individuals, in
IDUs with and without HIV infection, to compare the per-
formance of the two IGRAs in HIV-infected and HIV-
uninfected patients, to determine the concordance be-
tween the three diagnostic tools for LTBI (TST, QFT-G, and
QFT-GIT), and to assess the risk factors associated with
positive IGRAs.
Methods
This is a prospective, cross-sectional study conducted from
January 2008 to January 2010. We enrolled patients from a
regional hospital (E-Da Hospital) and a medical center
(Kaohsiung Veterans General Hospital) in southern Taiwan.
Study patients were invited to participate by announce-
ments from infectious diseases outpatient clinics and from
the methadone clinic providing care for IDUs. They were
grouped into HIV-uninfected and HIV-infected patients. The
study protocol was approved by the Institutional Review
Board of both hospitals.
All study patients received baseline medical evaluations
and a chest X-ray to rule out active TB infection. Symp-
tomatic patients were excluded. A questionnaire was
administered to collect demographic data, including sex,
age, underlying diseases, BCG vaccination status, and risk
factors for LTBI, such as having a history of TB disease or
contact with persons who had active TB disease. In HIV-
infected patients, HIV viral load and CD4 count drawn
within 3 months of study entry were recorded.
Whole blood (8 mL) was drawn for QFT-G (Cellestis Ltd.
Melbourne, Australia) and QFT-GIT (Cellestis, Melbourne,
Australia) prior to performing TST. Blood was processed
according to the manufacturer’s instructions.
TheQFT-G andQFT-GITwere interpreted as positive if the
IFN-g level in response to ESAT-6, CFP-10, or TB 7.7 was
0.35 IU/mL and 25% of the background value; the values
were interpreted as negative if the IFN-g level was<0.35 IU/
mL or <25% of the background value, with the IFN-g level in
response to mitogen (the positive control) reaching at least
0.5 IU/mL. The resultwas interpreted as indeterminate if the
IFN-g level was <0.35 IU/mL or <25% of background value
with the IFN-g level in response to mitogen<0.5 IU/mL, or if
the negative control was8.0 IU/mL, irrespective of the IFN-
g response to ESAT-6 or CFP-10 or TB 7.7.
The TST was performed by an intradermal injection of 2
tuberculin unit (RT-23; Statens Serum Institut, Copenhagen,
Denmark) on the volar surface of the forearm, and the diam-
eter of the induration was read 48e72 hours later by the
Mantouxmethod. InHIV-infected persons, TSTwas considered
positive when the indurationmeasured5mm. An induration
of 10 mm was considered positive in HIV-uninfected persons
without BCG vaccination, and 15 mm in HIV-uninfected
persons who have received BCG vaccination.
Statistical analysis
Data were analyzed using the Stata Statistical Software
version 10 (StataCorp LP, College Station, TX, USA).Categorical variables were compared using Pearson Chi-
square analysis or the Fisher’s exact test. Continuous vari-
ables were compared by Student t test or the Wilcoxon
rank-sum test. Concordance between the TST and QFT re-
sults was assessed by the kappa (k) coefficient. Strength of
agreement was considered poor if k  0.20 or less, fair if
k Z 0.20e0.40, moderate if k Z 0.40e0.60, substantial if
kZ 0.60e0.80, and optimal if kZ 0.80e1.00.22 Risk factors
for QFT and TST positivity were determined by multivari-
able logistic regression analysis. Age, HIV status, IDUs sta-
tus, and a history of TB exposure were included a priori in
the final multivariable model. QFT-GIT was used as the
reference standard as a surrogate for the diagnosis of LTBI
to calculate the sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of TST and
QFT-G.
Results
A total of 233 patients were recruited into this study [most
participants were men (nZ 198), 85%], with a mean age of
39.4 years (standard deviation, 10.2 years; range,
20.1e71.3 years). The study population included 147 (63%)
HIV-uninfected and 86 (37%) HIV-infected patients. Among
the 233 study participants, 137 (59%) were IDUs and most
were HIV uninfected (83.7% vs. 16.3%, p < 0.001). HIV-
uninfected patients were mostly IDUs (123, 83.7%) and
many were homeless, and had a history of living in a shelter
or prison (109, 80%). None of the HIV uninfected, non-IDUs
(24/147) recalled having exposures to TB. The median CD4
count in HIV-infected patients was 348 cells/mL. In patients
with HIV infection, 53 were men-who-have-sex-with-men
(61.6%), 15 were heterosexuals (17.4%), 14 were IDUs
(16.3%), and four were infected by blood transfusion (4.7%).
The mean age (38.9 years vs. 40.4 years, pZ 0.28) and the
BCG vaccination status (73.5% vs. 75.6%, pZ 0.72) were not
different in those with and without HIV infection. Patients
with HIV more frequently had a history of TB disease or
contact with patients with TB, whereas patients without
HIV more commonly lived or worked with those who are
homeless or those in a shelter or prison (Table 1).
Prevalence of LTBI estimated by IGRA
The overall prevalence of LTBI was estimated to be 15.9%
[95% confidence interval (CI): 11.2e20.6] by QFT-G and
20.6% (95% CI: 15.4e25.8) by QFT-GIT positivity (pZ 0.19).
HIV-infected individuals were significantly less likely to
have positive QFT-G results [3.5% vs. 23.1%, p < 0.001,
adjusted odds ratio (aOR) 0.40, p Z 0.25] and QFT-GIT
results [7.0% vs. 28.6%, p < 0.001, aOR 0.28, p Z 0.05]
than persons without HIV infection. Indeterminate re-
sponses occurred more frequently in HIV-infected persons
when using QFT-G (9.3% vs. 0.7%, p Z 0.002), but not with
QFT-GIT (2.3% vs. 2.0%, p Z 1.00). QFT-GIT had a nonsig-
nificantly higher rate of positivity than QFT-G in both HIV-
uninfected (28.6% vs. 23.1%, p Z 0.29) and HIV-infected
patients (7.0% vs. 3.5%, p Z 0.50; Fig. 1). Low CD4 cell
counts did not have a significant impact on the results of
QFT-G and QFT-GIT in HIV-infected persons (Table 2).
Indeterminate results in HIV-infected persons were mostly
Table 2 Results of QuantiFERON-TB Gold (QFT-G) and
QuantiFERON-TB Gold In-Tube (QFT-GIT) stratified by CD4
cell counts in HIV-infected persons (n Z 86)
Test Result CD4 < 200
(n Z 22)
CD4  200
(n Z 64)
p
QFT-G Positive 0 (0.0) 3 (4.7) 0.61
Indeterminate 1 (4.6) 7 (10.9)
QFT-GIT Positive 1 (4.6) 5 (7.8) 0.10
Indeterminate 2 (9.1) 0 (0.0)
Data are presented as n (%).
CD4 Z cluster of differentiation 4; HIV Z human immunodefi-
ciency virus; QFT-G Z QuantiFERON-TB Gold; QFT-
GIT Z QuantiFERON-TB Gold In-Tube.
Table 1 Baseline demographic and clinical characteristics
of HIV-infected and -uninfected patients (n Z 233)
Characteristics Non-HIV
(n Z 147)
HIV
(n Z 86)
p
Demographics
Age (y, mean  SD)
(range)
38.9 (8.4)
(21.1e62.9)
40.4 (12.6)
(20.1e71.3)
0.28
Sex, male 119 (81.0) 79 (91.9) 0.03
HIV risk factor
IDU 123 (83.7) 14 (16.3) <0.001
MSM d 53 (61.6) d
Heterosexual d 15 (17.4) d
Transfusion d 4 (4.7) d
BCG vaccination 108 (73.5) 65 (75.6) 0.72
Risk factors for TB disease
Smoking 90 (61.2) 30 (34.9) <0.001
Lived or worked in
homeless shelter or
prison
103 (70.1) 11 (12.8) <0.001
Exposure to TBa 4 (2.7) 26 (30.2) <0.001
a History of exposure to TB includes past TB disease or contact
with patients who had TB.
Data are presented as n (%), unless otherwise indicated.
BCG Z Bacillus Calmette-Gue´rin; HIV Z human immunodefi-
ciency virus; IDU Z intravenous drug users; MSM Z men who
have sex with men; SD Z standard deviation;
TB Z tuberculosis.
732 W.-C. Lin et al.due to a lack of response to mitogen (7/8, 87.5% in QFT-G
and 2/2, 100% in QFT-GIT).Prevalence of LTBI estimated by TST
TSTwas performed in 92 patients (18 HIV-uninfected and 74
HIV-infected patients). The mean diameter of TST indura-
tion was 4.2 mm (range, 1.0e20.0 mm). Fig. 2 showed theFigure 1. The prevalence of latent tuberculosis infection
estimated using two interferon-g release assays (QuantiFERON
TB-Gold and QuantiFERON-TB Gold In-Tube test) in HIV-
infected (n Z 86) and HIV-uninfected patients (n Z 147).
HIVZ human immunodeficiency virus; QFT-GZ QuantiFERON-
TB Gold; QFT-GIT Z QuantiFERON-TB Gold In-Tube.distribution of the size of TST induration in the two groups.
When using a 5-mm cutoff criterion, the TST result was
positive in 17 HIV-infected patients (23.0%) and 18 HIV-
uninfected patients (100.0%). When using a 10-mm cutoff
criterion, the TST result was positive in 10 HIV-infected
patients (13.5%) and 14 HIV-uninfected patients (77.8%).
TST, interpreted at any cutoff criteria, was significantly less
frequently positive in HIV-infected persons compared with
HIV-uninfected persons (Fig. 2).Agreement between the two IGRAs and TST and
IGRA in HIV-infected and HIV-uninfected patients
The concordance between QFT-G and QFT-GIT was very
poor in HIV-infected patients (k Z 0.05); however, the
concordance was moderate in HIV-uninfected patients
(kZ 0.50). The overall agreement between TST and QFT-G
ranged from 17.7% to 82.4% in HIV-uninfected and from
75.7% to 94.3% in HIV-infected persons for TST cutoffs
varying between 5 mm and 15 mm, and the concordance
was fair (k < 0.5). The overall agreement between TST andFigure 2. Tuberculin skin test (TST) positivity using different
cutoff values in HIV-infected and HIV-uninfected patients
(nZ 92). a TST cutoff value was 15 mm for BCG-vaccinated and
10 mm for BCG-unvaccinated persons. HIV Z human immuno-
deficiency virus.
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from 81.9% to 91.7% in HIV-infected persons for TST cutoffs
varying between 5 mm and 15 mm, but the concordance
was poor (k < 0.5). Excluding those with both indetermi-
nate QFT-G and QFT-GIT results, 14 (15.4%) had discordant
TSTþ/QFTe and five (5.5%) had discordant TSTe/
QFT þ results; 3/5 had nonreactive TST indurations. There
was poor concordance between the TST and IGRA (both
QFT-G and QFT-GIT) results using any of the TST cutoff
values, especially in HIV-infected patients (Table 3).
Risk factors for a positive IGRA
In multivariate analysis, significant risk factors for QFT-G
positivity included age (aOR Z 1.98, p Z 0.03) and IDUs
(aOR Z 4.33, p Z 0.05), after adjusting for HIV infection
and history of exposure to TB (Table 4). The risk factor for
QFT-GIT positivity included age (aOR Z 2.00, p Z 0.01),
after adjusting for IDU and history of exposure to TB. HIV-
infected patients were less likely to have positive QFT-GIT
(aOR Z 0.28, p Z 0.05; Table 4).
Sensitivity, specificity, PPV, and NPV
Using QFT-GIT as a reference standard for the diagnosis of
LTBI, both TST and QFT had low sensitivity (66.7% for TST
and 51.5% for QFT-G). However, QFT had a higher speci-
ficity than TST (TSTZ 82.5% vs. QFTZ 92.5), a higher PPV
(64.9% vs. 30.0%) but a lower NPV (87.4 vs. 95.7%) than TST
(Table 5).
Discussion
This study compared two IGRA tests with TST for the
diagnosis of LTBI in HIV-infected and HIV-uninfected adults
in a country with a low incidence of HIV, an intermediate
prevalence of TB, and a high BCG vaccination coverage. We
found that HIV-infected persons had a significantly lowerTable 3 Agreement between TST and interferon-gamma releas
Tests
Non-HIV (n Z 147)
QFT-G vs. QFT-GIT 80.6 (0.50, 0.34e0
Non-HIV (n Z 18)
QFT-G vs. TST (at various cutoff values)
 5 mm 17.7 (0.00, 0.00e0
 10 mm 41.2 (0.12,0.12e
 15 mm 82.4 (0.46, 0.004
15/10 mma 82.4 (0.46, 0.004
QFT-GIT vs. TST (at various cutoff values)
 5 mm 23.5 (0.00, 0.00e0
 10 mm 47.1 (0.17, 0.09e
 15 mm 76.5 (0.35, 0.13e0
15/10 mma 76.5 (0.35, 0.13e0
a TST cutoff value is 15 mm for BCG-vaccinated and 10 mm for BCG
CIZ confidence interval; HIVZ human immunodeficiency virus; QFT-
Tube; TST Z tuberculin skin test.response to both IGRAs and TST than HIV-uninfected per-
sons. IDU is a significant risk factor for LTBI using QFT-G. We
demonstrated that the two generations of IGRAs were not
comparable, and a high rate of discordance was found be-
tween IGRAs and TST at any cutoff criteria of TST indura-
tion. Increasing age, a known risk factor for LTBI, was
significantly associated with IGRAs on multivariable anal-
ysis, but not with TST.23
Our study demonstrated that HIV-infected persons were
significantly less likely than HIV-uninfected persons to have
a positive QFT-GIT. Previous studies reported a lower
response rate in HIV-infected persons with low CD4 counts
of <200 cells/mL.21,24e26 Because IGRAs depend predomi-
nantly on the CD4 recognition of M. tuberculosis antigens,27
absolute CD4 cell counts affect test performance in HIV-
infected persons.28 In our study, 25.6% (22/86) had CD4
cell counts <200 cells/mL, and had lower IGRA-positive
rates, but these were nonsignificant. Factors other than
CD4 counts may influence QFT positivity. It is advisable that
a repeat testing of IGRAs should be performed when CD4
counts are >200 cells/mL in individuals with an initially low
CD4 cell count and a nonreactive IGRA result.
A high prevalence of LTBI was observed among IDUs,
reaching 37.2%. This was similar to previous studies, where
the prevalence of LTBI in IDUs was 14e28% using TST29,30
and 34% by IGRA.31 IDU is a known risk factor for LTBI due
to increased exposure in crowded environments and
incarceration in correctional facilities.26,32 IDU was associ-
ated with a fourfold risk of LTBI using QFT-G. Co-infection
with HIV in IDUs was associated with a reduced rate of IGRA
positivity using either QFT-G (26.0% vs. 14.3%, pZ 0.57) or
QFT-GIT (31.7% vs. 7.1%, p Z 0.06). IGRAs are effective
screening tools for IDU, and can avoid the confounding
factors that limit the usefulness of TST, including HIV co-
infection and difficulty in returning for the TST reading.
In the current study, we found that the QFT-GIT assay
may be more sensitive than the QFT-G assay, as it had a
higher overall rate of positivity (20.6% vs. 15.9%, pZ 0.19);
in addition, indeterminate responses in those with HIVe assays in HIV-infected and -uninfected patients
Overall agreement % (kappa value, 95% CI)
HIV (n Z 86)
.66) 89.5 (0.05, 0.27e0.17)
HIV (n Z 74)
.00) 75.7 (0.04,0.12e0.19)
0.35) 85.7 (0.11, 0.09e0.31)
e0.93) 94.3 (0.02, 0.22e0.18)
e0.93) 94.3 (0.02, 0.22e0.18)
.00) 81.9 (0.31, 0.12e0.50)
0.44) 88.9 (0.37, 0.15e0.59)
.82) 91.7 (0.02, 0.19e0.15)
.82) 91.7 (0.02, 0.19e0.15)
-unvaccinated patients.
GZ QuantiFERON-TB Gold; QFT-GITZ QuantiFERON-TB Gold in-
Table 4 Risk factors for latent tuberculosis infection based on QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube test
positivity
Risk factor QuantiFERON-TB Gold (QFT-G)a QuantiFERON-TB Gold in-Tube (QFT-GIT)b
Crude odds
ratio (95% CI)
p Adjusted odds
ratioc (95% CI)
p Crude odds
ratio (95% CI)
p Adjusted odds
ratioc (95% CI)
p
Sex (male) 2.34 (0.68e8.09) 0.18 1.44 (0.38e5.50) 0.59 1.52 (0.55e4.18) 0.42 1.21 (0.39e3.72) 0.74
Aged 1.90 (1.11e3.27) 0.02 1.98 (1.08e3.64) 0.03 1.93 (1.19e3.13) 0.007 2.00 (1.18e3.42) 0.01
HIV 0.13 (0.04e0.44) 0.001 0.40 (0.09e1.89) 0.25 0.19 (0.08e0.46) <0.001 0.28 (0.08e0.97) 0.05
IDU 9.44 (2.80e31.83) <0.001 4.33 (1.04e18.08) 0.05 4.57 (2.03e10.32) <0.001 1.77 (0.63e4.99) 0.28
Sexual transmissione 0.06 (0.01e0.45) 0.006 0.30 (0.02e5.79) 0.42 0.22 (0.08e0.59) 0.002 3.63 (0.27e48.74) 0.33
BCG vaccination 1.65 (0.68e3.99) 0.27 1.51 (0.59e3.88) 0.40 1.67 (0.75e3.69) 0.21 1.65 (0.71e3.83) 0.25
Smoking 8.90 (1.16e68.32) 0.04 2.29 (0.24e22.05) 0.47 6.76 (1.54e29.75) 0.01 3.15 (0.55e17.96) 0.20
Lived or worked in
homeless
shelter, prison
4.28 (1.78e10.32) 0.001 0.55 (0.14e2.14) 0.39 3.61 (1.71e7.59) 0.001 1.04 (0.29e3.76) 0.96
Exposure to TB 0.16 (0.02e1.25) 0.08 0.30 (0.03e2.80) 0.29 0.37 (0.11e1.30) 0.11 0.74 (0.18e3.13) 0.69
TST positivityf 0.88 (0.24e3.18) 0.85 6.26 (0.87e45.27) 0.07 1.69 (0.61e4.67) 0.31 10.15 (2.17e47.49) 0.003
CD4 < 200 0.69 (0.00e6.64) 0.77 0.33 (0.00e3.66) 0.39 0.62 (0.07e5.65) 0.67 0.62 (0.01e6.07) 1.00
a Nine patients with indeterminate results on the QuantiFERON-TB Gold test were excluded.
b Five patients with indeterminate results on the QuantiFERON-TB Gold In-Tube test were excluded.
c Multivariate analysis was adjusted for age, HIV, IDU, and exposure to TB.
d Age was divided into three groups (<30 years old, 30e39 years old, and 40 years old). There was a significantly increasing trend of
QFT-G positivity with increasing age (OR Z 1.79, 95% CI Z 1.11e2.90, p Z 0.02).
e Risk factors for sexual transmission included MSM and heterosexuals.
f In HIV-infected persons, TST was considered positive when the induration measured 5 mm or greater. An induration of 10 mm was
considered positive in HIV-uninfected persons without BCG vaccination, and 15 mm or greater in HIV-uninfected persons who have
received BCG vaccination.
BCG Z Bacillus Calmette-Gue´rin; CD4 Z cluster of differentiation 4; CI Z confidence interval; HIV Z human immunodeficiency virus;
IDU Z intravenous drug users; MSM Z men who have sex with men; TB Z tuberculosis; TST Z tuberculin skin test.
734 W.-C. Lin et al.infection were not increased, as was observed in QFT-G.
The overall agreement was poor between the two IGRAs.
A previous study found a fair to good agreement between
QFT-G and QFT-GIT (75.4%, k Z 0.51) in unemployed
workers, and suggested that discordance between the two
generations of IGRA may arise from increased sensitivity
due to either the extra M. tuberculosis-specific antigen
used with the in-tube method (TB antigen 7.7) or immedi-
ate incubation of whole blood in tube with the antigens.33
Other possible causes for inter-test discordance are small
variations between duplicate IGRAs,28 variable immune
responses due to changing CD4 cell counts, medications,
stress, and infection. The explanations for indeterminate
results that may impair QFT-G performance are improper
collection, storage, incubation, and processing of blood, as
well as a time lag between drawing blood samples. Based
on our study, QFT-G and QFT-GIT results were incompa-
rable, in both HIV-infected and -uninfected persons.
The agreement was poor to fair between TST and QFT
(agreement Z 17.6e94.3, k Z 0.22e0.46), with particu-
larly lower kappa coefficients in the HIV-infected groupTable 5 Sensitivity, specificity, PPV, and NPV of TST and QFT-G u
Sensitivity (95% CI) Specificity (95
TST (%) 66.7 (29.9e92.5) 82.5 (72.4e90
QFT-G (%) 51.5 (36.1e65.9) 92.5 (87.5e95
CI Z confidence interval; NPV Z negative predictive value; PPV Z
GIT Z QuantiFERON-TB Gold in-Tube; TB Z tuberculosis; TST Z tub(k Z 0.02e0.37). Discordance between QFT and TST may
be due to variation in the amount and type of tuberculin
solution used as well as due to heterogenicity in BCG
vaccination rates, exposure to atypical mycobacteria, local
TB incidence, estimated time since LTBI, and immune
status.21,33e35
Discordant TSTþ/QFTe results were found in 15.4% (14/
91) of our study patients, most of whom had received BCG
vaccination (12/14, 85.7%) and were HIV infected (12/14,
85.7%). Only three HIV-infected persons had CD4 counts
<200 cells/mL, and all were receiving ART. Discordance
between TST and IGRA with TSTþ/IGRA results was
strongly associated with cross-reactivity with NTM and BCG
vaccination status, especially in low TB endemic areas and
in populations with low risk for TB exposure.34 A clear
proportional relationship was observed between T cell
count and the level of IFN-g response in those with CD4 cell
count <500 cells/mL.36 The higher prevalence of LTBI
among HIV infected, using TST (23.0%, 95% CI: 13.2e32.8)
compared with IGRA (10.5%, 95% CI: 3.9e17.1), in our study
may be due to false reactivity associated with BCGsing QFT-GIT as the reference standard for latent TB infection
% CI) PPV (95% CI) NPV (95% CI)
.1) 30.0 (11.9e54.3) 95.7 (87.8e99.1)
.9) 64.9 (47.5e79.8) 87.4 (81.7e91.9)
positive predictive value; QFT-G Z QuantiFERON-TB Gold; QFT-
erculin skin test.
Latent TB infection by IGRA and TST in HIV and IDUs 735vaccination.16,34,35 False-positive TST results increase the
cost of TB screening with additional procedures such as
chest radiographs and unnecessary drug treatment.37
Discordant TSTe/QFT þ results (5/91, 5.5%) may be
attributable to either false-positive QFT results or better
sensitivity of IGRAs over TST. A negative TST may have been
due to anergy in HIV infection (3/5, 60%). When using the
QFT-GIT as a reference standard for diagnosis of LTBI, both
QFT and TST had a low sensitivity, but QFT had a higher
specificity, higher PPV, and lower NPV than TST. The reli-
ability and validity of TST and IGRAs can be influenced by
several confounding factors, including the immune status,
cross-reactions to BCG or NTM, and the prevalence local TB
burden.34 To increase the PPV and reduce the number of
false positives, the use of a risk-stratified interpretation, as
has been used for TST, was suggested.38 We suggest
that the use of TST alone may not be accurate in the
diagnosis of LTBI in HIV-infected persons, especially in pa-
tients who had received BCG vaccination. Use of IGRAs may
be more accurate in the diagnosis of LTBI in this high-risk
group.
There are several limitations in this study. First, the
control group consisted of mostly IDUs rather than healthy
individuals, which may augment the negative association of
an IGRA response in HIV-infected persons and may not be
generalizable to non-IDU populations. However, the selec-
tion of HIV-uninfected IDUs as a control group allowed for
the clarification of the risk of LTBI in IDUs with and without
HIV infection. Second, other risk factors associated with
LTBI, such as diabetes mellitus, hemodialysis, or other
immunocompromised status, were not analyzed due to the
small number of patients harboring the risk factor. How-
ever, this study was aimed to investigate the risk factors,
HIV infection, and IDU. Third, not all patients underwent
TST, especially the HIV-uninfected patients. Based on our
study and previous reports, anergy is frequently observed in
HIV-infected persons and therefore TST is of limited use in
this group. Finally, we did not record the initial or nadir CD4
cell counts and the use of antiretroviral agents in the HIV-
infected patients, and therefore, the impact of nadir CD4
cell counts on IGRA and TST response cannot be evaluated.
In conclusion, this study demonstrated that IGRAs are
useful diagnostic tests in HIV-infected and -uninfected
persons in countries with a large number of BCG-vaccinated
individuals. However, HIV infection is associated with false-
negative IGRA results, and a negative or indeterminate
result should be interpreted with caution. Based on our
study, TST alone may be unreliable in the diagnosis of LTBI
in BCG-vaccinated and/or HIV-infected persons, and we
recommend the use of IGRAs in these populations. IGRAs
are better correlated with risk factors for LTBI, such as age,
compared with TST. Further longitudinal studies need to be
conducted to determine the predictive value for the
development of active TB disease in HIV-infected patients
and IDUs, and identify individuals who will benefit from
LTBI treatment, especially in intermediate TB and low HIV-
burden countries.Conflicts of interest
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